FDA Says On Dec 18, Said It Got Postmarketing Safety Data On Thromboembolic Events, Including Serious & Fatal Outcomes, In Patients Treated With Andexxa; Astrazeneca Submitted Request To Voluntarily Withdraw BLA For Andexxa For Commercial Reasons; Based On Available Data, FDA Considers Risks Of Andexxa To Outweigh Its Benefits; Andexxa Will No Longer Be Manufactured For Or Sold In U.S. By Astrazeneca After Dec 22, 2025